139 related articles for article (PubMed ID: 20463598)
1. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
2. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
3. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.
Hedlund G; Eriksson H; Sundstedt A; Forsberg G; Jakobsen BK; Pumphrey N; Rödström K; Lindkvist-Petersson K; Björk P
PLoS One; 2013; 8(10):e79082. PubMed ID: 24194959
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
5. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
6. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
7. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
8. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
9. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
10. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
11. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
12. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
13. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
14. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
[TBL] [Abstract][Full Text] [Related]
15. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
Shinoda M; Kudo T; Suzuki M; Katayose Y; Sakurai N; Saeki H; Kodama H; Fukuhara K; Imai K; Hinoda Y; Matsuno S
Cancer Res; 1998 Jul; 58(13):2838-43. PubMed ID: 9661899
[TBL] [Abstract][Full Text] [Related]
16. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
18. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
[TBL] [Abstract][Full Text] [Related]
19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
20. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
Eisen T; Hedlund G; Forsberg G; Hawkins R
Curr Oncol Rep; 2014 Feb; 16(2):370. PubMed ID: 24445502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
